AI-curated news for your industry

A Wall Street niche is booming as private biotechs increasingly use reverse mergers with public shells to access Nasdaq investors, with roughly two dozen deals announced by August 2026—more than double all of 2025. The strategy, once stigmatized, has gained legitimacy through Fairmount Funds' model of pairing fallen biotechs with well-financed private companies. While IPOs are also rebounding, reverse mergers offer speed and certainty, attracting institutional investors and Chinese-originated assets. However, the supply of high-quality shells may become a bottleneck, potentially affecting which companies get funded and which medicines get developed.

The U.S. FDA approved Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) in combination with chemotherapy (with or without immunotherapy Tevimbra) for first-line treatment of HER2-positive gastrointestinal cancers on Tuesday. The drug had previously received accelerated approval for advanced biliary tract cancer, generating $24.8 million in related revenue in 2025. Analysts estimate the market opportunity for the new indication exceeds $1.5 billion, and the FDA imposed no excessive safety restrictions. Jazz and partner Zymeworks will share milestone payments, with Zymeworks having already received $250 million, plus $1.3 billion in future milestones and royalties.

The latest MassBio industry report indicates that in the first half of 2026, Massachusetts biotech companies secured nearly $3.5 billion in venture capital, up 25% year-over-year, with eight Boston-area biotech companies completing IPOs. However, funding is concentrating in more mature companies, with the average seed round amount dropping to $4.65 million, while the average Series A round approaches $80 million, leaving early-stage startups facing financing difficulties. The report also includes a first-ever "China Watch" section, showing that China's drug pipeline grew 36.2% year-over-year, surpassing Europe for the first time.

Regenxbio's gene therapy RGX-121 has encountered another FDA clinical hold in clinical trials due to "possibly" benign masses found on spinal MRIs of five subjects. The company stated that patients are asymptomatic and clinically stable, but its plan to resubmit the marketing application in June has been shelved. Previously, the therapy had been placed on hold in January due to safety concerns and was rejected by the FDA in March.

Cellares, a biotech startup focused on cell therapy manufacturing, announced a restructuring two months after completing a $327 million Series D funding round, planning to lay off 100 employees due to the loss of an unnamed pharmaceutical partner. The layoffs mainly affect software engineers, quality control, design, and manufacturing specialists, and are expected to take effect on October 20.

Roche announced a licensing agreement with Hanmi Pharmaceutical to obtain global rights outside South Korea for the novel obesity drug HM17321. The drug aims to promote weight loss while preserving muscle tissue and is considered a next-generation therapy targeting potential deficiencies of GLP-1 class drugs. The deal includes an upfront payment of $190 million, with milestone payments potentially reaching up to $2.3 billion.

The competition between Eli Lilly and Novo Nordisk in the weight-loss market is extending from the supply side to pricing and public perception. Latest earnings reports and multiple surveys indicate that affordability, physician prescribing preferences, and social stigma are becoming key factors influencing the trajectory of the GLP-1 drug market.

Vertex's Journavx, the first new pain drug in decades, has revived interest in pain research, but its modest sales and the difficulty of developing better painkillers pose challenges. Companies like Latigo and SiteOne are pursuing ion channel blockers, while researchers explore drug combinations. The field must soon deliver assets worth rallying around beyond Journavx to sustain major investments.